The terms, per the grant. On May 10, 2022, Seagen was issued US11325980B2, “Combination therapy using a LIV1-ADC and a chemotherapeutic.” The CPC stack — C07K 16/3015 (the targeting antibody), A61K 47/6803/6811/6851 (conjugation), plus the A61K 31/337/555/704 chemotherapy combinations — claims the conjugate used together with specific chemotherapies.

The claim set is tighter than the title, and the specificity is what makes it a deal-relevant asset. Independent claim 1 does not cover any LIV-1 conjugate plus any partner agent; it covers administering a LIV-1 antibody-drug conjugate together with "a checkpoint inhibitor," where the conjugate is "a humanized hLIV22 antibody conjugated to a vcMMAE" — a named antibody on a valine-citrulline-monomethyl auristatin E linker-payload. That is a particular molecule paired with a particular class of combination partner, which is exactly the kind of bounded claim a method-of-use license is written around.

Why combination claims matter to a deal: a combination-therapy patent protects how a drug is used alongside another agent, which can extend exclusivity and open additional licensing and co-development structures beyond the base composition. For a franchise, combination IP is a way to keep refreshing the protective estate as the core molecule ages.

“The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.”— U.S. Patent No. 11,325,980 source

The dependent claims map the commercial surface of the grant. They reach defined tumor settings — breast cancer (claim 2), and within it "triple negative breast cancer, triple positive breast cancer, HER2-positive breast cancer, or hormone receptor positive cancer" (claim 3), with triple-negative called out separately (claim 4) — as well as "prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, lung cancer, a cervical cancer, a melanoma, or squamous cell carcinoma" (claim 5). They also fix a dosing envelope: a range "between 1.5 mg/kg and 4 mg/kg" of body weight (claim 6), a specific 2.5 mg/kg dose (claim 7), administration "once every 3 weeks" (claim 8), and "by intravenous injection" (claim 9). For a deals desk, each named indication and each dose point is a separate axis along which a label-expansion collaboration or method-of-use license can be scoped and priced.

The combination partner is itself claimed with specificity. The checkpoint inhibitor is defined as "an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, B7-DC-Fc, LAG3, or TIM3" (claim 10), narrowed to an anti-PD-1 antibody (claim 11), and then to named agents — "MEDI0680, AMP-224, nivolumab, pembrolizumab, or pidilizumab" (claim 12). Naming third-party checkpoint agents inside the claims is what makes this the kind of grant a co-development or combination deal references directly, because it defines whose product the combination is built around.

The structure point: combination grants support add-on deal structures — co-development, label-expansion collaborations, and method-of-use licenses — that layer on top of the composition license. For a model, they are incremental royalty-bearing assets tied to specific clinical uses rather than to the molecule alone. A grant that fixes the antibody, the linker-payload, the partner class, the indications and the dose gives a licensing desk discrete, separately negotiable units rather than one monolithic right.

What the grant does not promise: that the combination is approved, that it outperforms monotherapy, or that it forecloses all competing regimens. It is an exclusivity claim on a specific combination use — valuable, but use-specific, and bounded to the named hLIV22-vcMMAE conjugate and the recited checkpoint partners.

It is worth being precise about what an antibody-drug-conjugate franchise is and why combination IP extends its life, because that is the mechanism a model is pricing. The conjugate itself is the targeting antibody, here the humanized hLIV22 antibody, joined through a cleavable valine-citrulline linker to the cytotoxic payload monomethyl auristatin E. Composition-of-matter protection over that molecule is the base of the estate. A combination grant sits one layer up: it does not re-claim the molecule, it claims a way of using the molecule alongside a defined second agent. That distinction is why combination IP can keep generating new, separately datable exclusivity as the underlying composition matures, and why it expands the menu of deal structures available around a maturing franchise.

The way the dependent claims are tiered is itself a roadmap for licensing scope. The indication claims move from the broad ("breast cancer," claim 2) to the specific subtype ("triple negative breast cancer," claim 4), and separately enumerate a long list of other solid tumors (claim 5). The dosing claims move from a range (claim 6) to a single recited dose (claim 7) to a schedule (claim 8) and a route (claim 9). For a deals desk, that tiering means a license can be carved at whatever altitude a partner needs: a narrow method-of-use right for one tumor type and one dose, or a broader grant spanning the enumerated indications. Each cut is a different royalty base, and the claim structure is what makes those cuts cleanly definable rather than contested. The partner-agent claims do the same work on the other axis, stepping from a class of checkpoint inhibitors (claim 10) down to anti-PD-1 antibodies (claim 11) and then to specifically named molecules including nivolumab and pembrolizumab (claim 12). Naming third-party agents inside the claims is what lets a combination deal reference, with precision, whose product the protected regimen is built around, which in turn shapes any co-development or supply terms that follow.

The takeaway: when valuing a conjugate franchise, read the combination-therapy grants as franchise-extending assets layered on the core ADC. Seagen's May 2022 LIV-1 combination grant is a dated example of how combination claims add deal surface area — one indication, one dose, one named partner agent at a time.